NCT06777316: An ongoing trial by Cogent Biosciences, Inc.
This trial is ongoing. It must report results 2 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06777316 |
|---|---|
| Title | A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 22, 2025 |
| Completion date | March 31, 2027 |
| Required reporting date | March 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |